Handelsbanken Fonder AB Has $6.53 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Handelsbanken Fonder AB lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 30.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 156,970 shares of the company’s stock after purchasing an additional 36,697 shares during the quarter. Handelsbanken Fonder AB’s holdings in Moderna were worth $6,527,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of MRNA. Blue Trust Inc. raised its position in shares of Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after purchasing an additional 574 shares during the period. Raymond James & Associates raised its position in shares of Moderna by 19.7% during the third quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock worth $10,831,000 after purchasing an additional 26,657 shares during the period. International Assets Investment Management LLC raised its position in shares of Moderna by 10,687.1% during the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after purchasing an additional 316,552 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Moderna by 79.0% during the third quarter. Assenagon Asset Management S.A. now owns 13,159 shares of the company’s stock worth $879,000 after purchasing an additional 5,807 shares during the period. Finally, E. Ohman J or Asset Management AB acquired a new position in shares of Moderna during the third quarter worth approximately $942,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by insiders.

Moderna Stock Performance

Shares of MRNA opened at $35.53 on Friday. The business has a 50-day moving average of $38.04 and a 200 day moving average of $52.66. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The firm has a market cap of $13.67 billion, a P/E ratio of -3.83 and a beta of 1.59.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. UBS Group decreased their price target on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Wolfe Research assumed coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Finally, The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Moderna has an average rating of “Hold” and a consensus price target of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.